Search

everythinglearnresearchcommunity

for

Search:↓

About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.

New tools and criteria have been developed to better assess and treat pediatric lupus.

The new SLICC criteria for diagnosing lupus are more sensitive and accurate than the old criteria.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.

Hydroxychloroquine may help delay skin damage in lupus patients.

Non-adherence to medication in Egyptian SLE patients leads to more hospitalizations and symptoms.

Many patients with cutaneous lupus erythematosus experience hair loss and nail problems, which are important for diagnosis and treatment.

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

SLE and DM can coexist but are rare and need careful evaluation.

New tools were created to help lupus patients report their symptoms and impacts more accurately.

Hair loss is common in lupus patients and can be permanent or reversible, depending on the type, with various treatments available.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

Lupus is a complex disease that requires personalized treatment because it varies greatly between individuals.

Most patients with Cutaneous Lupus Erythematosus are young females, and dermatologists play a key role in diagnosis.

Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.

Early recognition and management of connective tissue diseases like lupus are crucial in young patients.

Skin symptoms are important for diagnosing and managing juvenile-onset systemic lupus erythematosus and usually get better with treatment.

Lupus patients' body image issues significantly affect their mental health and need more support.

Women with Systemic Lupus Erythematosus should have closely monitored pregnancies and avoid certain medications to improve their pregnancy outcomes.

The document concludes that anti-dsDNA antibodies are not unique to SLE and their use as indicators is doubtful, highlighting the need for better understanding and classification of the disease.

Pregnant women with Systemic Lupus Erythematosus have a higher risk of blood clotting problems.

Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.

The Polish Dermatological Society recommends personalized treatment for cutaneous lupus, including lifestyle changes, medications, and monitoring, with specific drugs for severe cases.

Gender-specific analysis could improve treatment for childhood systemic lupus erythematosus.

Lupus treatment requires a combination of drugs and therapies, with research needed for new options.

Different types of hair loss in lupus need careful diagnosis for proper treatment.

42% of SLE patients had thyroid issues, mostly hypothyroidism.

Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.

Hydroxychloroquine may help COVID-19 patients with lupus.